Title : S-Adenosylmethionine as a precision adjunct therapy to chemotherapeutic alkylating agents in attenuating side effects and improving outcomes in various cancers
Although the non-enzymatic methylation of cytosine by S-AdenosylMethionine to 5-methylcytosine and its subsequent spontaneous deamination to thymine in DNA at physiologic pH and temperature has been implicated in some cytosine to thymine point mutagenic cancers, cancers in general display a global hypomethylation of their DNA. S-AdenosylMethionine, therefore, may still possibly play a role as a potential rescue adjunct therapy to attenuate side effects and/or improve outcomes in certain cancers, particularly those treated with alkylating chemotherapeutic agents, much in the same way that folic acid is used as a rescue adjunct therapy when using antifolate chemotherapeutic agents. Clinical trials in support of this prospectus are, therefore, justified and any evidence obtained from such ongoing and/or concluded trials will be presented.
Audience Take Away:
- Specific scheduled dosage regimens of S-AdenosylMethionine as adjunct rescue therapy for each chemotherapeutic alkylating agent will be presented for clinicians and practitioners to make use of in their application of these agents to various cancers.
- Despite the precise specifics of such scheduled dosage regimens, the versatility of the alkylating chemotherapeutic agents in treating an array of different cancers allows for widespread application of this protocol throughout the field of oncology.